× TECHNOLOGY
SOFTWARE NETWORKING CLOUD IT SERVICES MOBILE SECURITY STORAGE IOT DATA ANALYTICS CYBER SECURITY ORACLE SAP BIG DATA
BUSINESS
DIGITAL MARKETING ERP RETAIL HEALTHCARE TELECOM
MAGAZINE
CURRENT ISSUE ARCHIVE
OPINION ABOUT US CONTACT US

Cancer patients get a breather through Mendel.ai

cancer patients get a breather through mendel ai

Dr. Karim Galil started Medel.ai which is an organized and an artificial intelligent system for cancer. The system finds a match with patients under a doctor’s care with the best diagnostic and treatment method available. The company has raised over $2M from ventures like DCM Ventures, Bootstrap Labs and Launch Capital. The new system comes as a blessing for many doctors and researchers who have been constantly facing hardships and failures in clinical trials and testing regarding cancer. Dr. Galil named the system after the father of modern genetics science – Gregor Mendel.

Clinical trials generate large amounts of data. The new startup could prove useful for doctors who are struggling and finding it difficult to manage and keep up on the massive amount of clinical data. The way Medel.ai works is quite similar to BenevolentBio, based out in UK. BenevolentBio finds the latest cutting-edge medical research by running through scientific papers.

But Medel.ai uses algorithms. It takes the medical information straight from clinicaltrials.gov and understands these medical documents. Further, it compares with the patient’s medical history and records. This search process is done within minutes, according to Dr. Galil. And the search results in a full personalized match and evaluates the patient’s condition, along with suggestions for treatments. 

True Story

Dr. Galil was tired and afraid of the number of failed cancer trials. He was upset about the number of patients he was losing to cancer. And with the number of clinical trials available, he was even more confused and tired of trying to find the solutions from these trials. This was when he decided to start his own intelligent system. And he is happy with the results Mendel.ai is providing. “A lung cancer patient, for example, might find 500 potential trials on clinicaltrials.gov, each of which has a unique, exhaustive list of eligibility criteria that must be read and assessed,” said Galil.

And it is not just him, even the patients are not just pleased but overwhelmed with Mendel.ai. It is looking forward to collaborate with Comprehensive Cancer and Blood Center (CCBC). And apart from CCBC, it is looking forward to integrate this system in other hospitals and cancer research centers. But, there is still a challenge that Mendal.ai has to face, and that is IBM’s Watson.

MAGAZINES